Document is current
Any future updates will be listed below
-
Authors
Vilaia, Alexandra
Bosman, Fred T.
Poulios, Christos
Pagni, Fabio
Pijuan, Lara
Esposito, Irene
Kovacevic, Bozidar
Syrnioti, Antonia
Belcaid, Zineb
Fassina, Ambrogio
Al Dieri, Raed
Matias-Guiu, Xavier
Eloy, Catarina https://orcid.org/0000-0001-7642-1280
-
Funding
Funding for this research was provided by:
Universidade do Porto
- License Information
-
More Information
Article History
Received: 6 March 2026
Revised: 20 April 2026
Accepted: 22 April 2026
First Online: 14 May 2026
Declarations
:
: Formal ethical approval was not required for this study, as it did not involve any patient data collection or impact on patient care.
: AV declares lectures and associated travel expenses: Agilent-Dako, MSD and AstraZeneca. FP declares lectures and editorial board: Roche Pharma Novartis, Leica, AstraZeneca, GSK, Lilly, Amgen, GSK, Janssen, MSD, Logibiotech, Mediko. LPA declares lectures: Roche Pharma, Pfizer, Janssen, Agilent-Dako and Astrazeneca; Advisory boards: Boheringer. XMG declares lectures and associated travel expenses: Roche Pharma, Qiagen, Ferrer Internacional, Novartis, Menarini, Biocartis, Agilent-Dako, Leica, Reig Jofre, Sysmex, MSD, Astrazeneca, BMS, GSK, Clovis; Advisory boards: AstraZeneca, Lilly, Amgen, GSK, Janssen, Illumina, MSD. CE consulted for MSD, Biocartis, Diapath, and Sakura.Other authors declare no conflicts of interest.The declared interests by the authors are not related to published content.
